Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
BUSINESS
Sawai, Asahi Kasei Reach Settlement in Teribone Patent Suit
Sawai Group Holdings said on October 21 that its subsidiary Sawai Pharmaceutical had reached a settlement with Asahi Kasei Pharma over a patent infringement lawsuit involving the osteoporosis drug Teribone (teriparatide). Under the settlement, concluded on October 20, Sawai will…
To read the full story
Related Article
- Sawai to End Teribone Generic Sales following Patent Settlement
February 26, 2026
- Japan to Delist 387 Drugs from NHI Price List, Including Renivace
February 16, 2026
- Sawai Ordered to Pay 3 Billion Yen in Damages in Teribone Suit, Set to Appeal
September 30, 2024
- Osaka Court Bars Sawai’s Teribone Generic over Manufacturing Patents
September 6, 2023
- Asahi Kasei Sues Sawai over Manufacturing Method of Teribone Generic
May 11, 2022
BUSINESS
- Takeda Returns to Core Profit Growth, CEO Confident in Trajectory
October 30, 2026
- Novartis Japan President Pullicino to Step Down for Global Role
October 30, 2026
- Lilly’s Imulrio Reaches Japan Market 10 Months after Approval
October 30, 2026
- Ono’s First-Half Operating Profit Up 11% Despite Forxiga Sales Hit
October 30, 2026
- Shionogi Logs Record H1 Revenue as Acquisitions Pay Off
October 30, 2026
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…